Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
25- 5d agoPre-market26.10.20 22:26424B3Offering#●●●#●●●
Freenome, Inc.Bullish
Freenome has launched 'SimpleScreen Lung,' a blood-based test for early lung cancer detection, which can be combined with its FDA-approved colorectal cancer test to screen for both cancers in a single blood draw. The new test demonstrated 85% sensitivity and a 99.8% negative predictive value in clinical studies, marking a significant expansion of the company's personalized cancer detection portfolio.…more
$13.02+1.80%vs prev closeView filingShare
- 5d agoPre-market26.10.20 21:538-KKey event
Freenome, Inc.
Freenome has launched 'SimpleScreen Lung,' a blood-based test for early lung cancer detection, and introduced a combined offering with its FDA-approved colorectal cancer test to screen for both cancers via a single blood draw. The SimpleScreen Lung test demonstrated 85% sensitivity and a 99.8% negative predictive value in clinical validation, expanding the company's personalized cancer detection portfolio.…more
$13.02+1.80%vs prev closeView filingShare - 9.23After-hours26.09.24 06:06S-8Offering
Freenome, Inc.
Following the completion of its business combination on July 20, 2026, Freenome has registered 13,200,919 shares of common stock to support its 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan. This registration includes 2,466,114 shares reserved for future issuance, 8,272,601 shares for exchanged legacy options, and 2,462,204 shares for the employee stock purchase program.…more
$13.02+1.80%vs prev closeView filingShare
24 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 21:30#●●●#●●●
Freenome Launches SimpleScreen Lung Test and Expands Cancer Detection Portfolio…more
Freenome announced the launch of its blood-based SimpleScreen Lung test, which can be combined with its existing colorectal cancer screening option. While this expands the company's personalized cancer detection portfolio, investors should monitor the regulatory progress and clinical adoption of these new diagnostic offerings.…more
$13.02+1.80%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.15After-hours26.10.16 05:29
●●●●●●●● ●●●●● ●●●●●●
Freenome announced that it will release its financial results for the third quarter of 2026 after the market closes on November 10. A conference call will follow the announcement to discuss the company's financial performance.…more
$13.02+1.80%vs prev close - 10.11Closed26.10.12 02:00
●●●●●●●● ●●●●● ●●●●●●
Freenome announced updated clinical data showing improved sensitivity for detecting advanced precancerous lesions in its 'SimpleScreen CRC' blood-based test. The company plans to leverage this iterative performance improvement strategy across its broader multi-cancer diagnostic pipeline.…more
$13.02+1.80%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report